.

Bispecific antibody fares well against faricimab, two gene therapies extend treatment intervals

LAS VEGAS — OLN324, a VEGF and Ang-2 inhibitor for wet age-related macular degeneration, achieved improvements in anatomy and retinal fluid that were comparable to faricimab, according to a speaker at Clinical Trials at the Summit. “In the JADE study, we looked at two doses of OLN324 (Ollin Biosciences), 2 mg and 4 mg, and this was compared to faricimab,” Arshad Khanani, MD, MA, FASRS, of Sierra Eye Associates in Reno, Nevada, told Healio. “The JADE study included patients with neovascular AMD who were treatment-naive as well as DME.” {{VIDEO}} According to Khanani, who focused on neovascular

Eye, Published online: 25 January 2025; doi:10.1038/s41433-025-03616-51-Year real-world outcomes of faricimab in previously treated neovascular age-related macular degeneration

LAS VEGAS — OLN324, a VEGF and Ang-2 inhibitor for wet age-related macular degeneration, achieved improvements in anatomy and retinal fluid that were comparable to faricimab, according to a speaker at Clinical Trials at the Summit. “In the JADE study, we looked at two doses of OLN324 (Ollin Biosciences), 2 mg and 4 mg, and this was compared to faricimab,” Arshad Khanani, MD, MA, FASRS, of Sierra Eye Associates in Reno, Nevada, told Healio. “The JADE study included patients with neovascular AMD who were treatment-naive as well as DME.” {{VIDEO}} According to Khanani, who focused on neovascular

.

Comparison of discharge & readmission rates between Faricimab & aflibercept in UK patients with nAMD, whilst stratifying these rates by lesion type.

Background/aims To evaluate real-world, short-term anatomical and functional outcomes of faricimab versus aflibercept 2 mg in diabetic macular oedema (DMO).Methods This retrospective, parallel-cohort comparative study included 300 consecutive patients with DMO from Moorfields Eye Hospital. Eligible eyes were treatment-naïve and treatment-experienced not receiving therapy for ≥6 months and subsequently initiated on loading phase of faricimab or aflibercept 2mg. Follow-up was 4 months. Data were collected from the Moorfields electronic medical records system. Changes in visual acuity (VA) and central subfield thickness (CST) from baseline to the fourth injection were analysed using multiple linear regression adjusted for baseline covariates (age, gender, ethnicity, diabetes type, baseline retinopathy status, baseline VA or CST and treatment interval).Results Of 300 eyes enrolled, 292 were ultimately analysed (191 aflibercept; 101 faricimab), with 246 eyes (84.2%) completing follow-up. Mean unadjusted VA gain was +3.9±10.4 letters with aflibercept and +5.2±11.8 letters with faricimab. Adjusted marginal mean VA gain was +4.2 letters for aflibercept and +4.7 letters for faricimab, with a non-significant difference of –0.5 letters (p=0.7). Baseline VA and treatment interval were significant predictors of functional response, with baseline VA exerting approximately 3.4 times the impact of treatment interval. Mean CST reduction was 87.3±106.1 µm with aflibercept and 113.1±136.7 µm with faricimab. Adjusted mean reductions were 95.4 µm and 99.8 µm, respectively (difference –4.4 µm, p=0.7). Baseline CST was the only independent predictor of anatomical response.Conclusion Faricimab and aflibercept achieved comparable short-term anatomical and functional outcomes, with greater anatomical improvement associated with higher baseline CST and larger visual gains observed with lower baseline VA. Treatment interval influenced functional response, underscoring the importance of timely therapy. Baseline disease features and treatment adherence are key determinants of early outcomes, rather than drug selection.

Picture of the back of the eye showing intermediate age-related macular degeneration. Credit: National Eye Institute Since July 2024, faricimab has also been approved in Europe for the treatment of visual impairment due to macular edema secondary to retinal vein occlusion. The German Institute for Quality and Efficiency in Health Care (IQWiG) has now examined in an early benefit assessment whether faricimab offers patients benefits over ranibizumab or aflibercept.

Real-world case series suggests caution with even mild IOI.

Eye, Published online: 11 June 2026; doi:10.1038/s41433-026-04612-zClinical characteristics and outcomes of intraocular inflammation following intravitreal faricimab for neovascular age-related macular degeneration: a single-centre retrospective study

Eye, Published online: 04 August 2026; doi:10.1038/s41433-026-04710-yReal-world comparative effectiveness of faricimab versus aflibercept 2 mg in treatment-naïve exudative neovascular AMD patients treated with a treat-and-extend regimen

WAIKOLOA, Hawaii — Real-world, 12-month results demonstrated efficacy, safety and durability for faricimab as a treatment for retinal vein occlusion, according to a speaker at Retina 2026. In light of faricimab’s approval for retinal vein occlusion in 2023, its widespread adoption has yielded opportunities to investigate its real-world impact on larger patient populations, Durga Borkar, MD, MMCi, said during a presentation. “FARETINA-RVO is a retrospective, real-world study that leverages data from the American Academy of Ophthalmology’s IRIS registry,” Borkar said. “To be included in this

<div xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="section"> <a class="named-anchor" id="st1"> <!-- named anchor --> </a> <h5 c...

Für die feuchte Form der altersabhängigen Makula-Degeneration (AMD) stehen mittlerweile mehrere medikamentöse Behandlungsmöglichkeiten zur Verfügung.

NEW YORK — In this presentation from OSN New York Retina, Ferhina S. Ali, MD, MPH, discusses how real-world experience with new anti-VEGF therapies is measuring up to what was seen in clinical trials. She said real-world outcomes are generally poorer than…

Editor’s note: This is a developing news story. Please check back soon for updates. The FDA approved an updated label for Vabysmo for the treatment of macular edema following retinal vein occlusion beyond 6 months, according to a Genentech press release. Vabysmo (faricimab-svoa) is a bispecific antibody that inhibits angiopoietin-1 and VEGF-A. It is also approved for the treatment of neovascular age-related macular degeneration and diabetic macular edema. It was approved for macular edema due to retinal vein occlusion (RVO) in 2023, and the label update allows patients to continue using it

Editor’s note: This is a developing news story. Please check back soon for updates. The FDA approved an updated label for Vabysmo for the treatment of macular edema following retinal vein occlusion beyond 6 months, according to a Genentech press release. Vabysmo (faricimab-svoa) is a bispecific antibody that inhibits angiopoietin-1 and VEGF-A. It is also approved for the treatment of neovascular age-related macular degeneration and diabetic macular edema. It was approved for macular edema due to retinal vein occlusion (RVO) in 2023, and the label update allows patients to continue using it